His work investigates the neuroendocrine regulation of body composition and the physiological consequences of fat distribution on cardiovascular disease and inflammation.

Subsequent studies examined the mechanisms and demonstrated reduced area under the curve per peak, but maintenance of the GH pulse generator in such patients.

[11] Tesamorelin was also investigated in generalized obesity and showed significant effects to reduce cIMT, inflammatory markers, lipids and visceral adiposity.

He also recently proposed the first use of tilmanocept as a CD206 specific imaging agent for arterial inflammation, with success in HIV published in JID.

[16] In recognition of this work, he has led the REPRIEVE trial, a global primary prevention study performed in 12 countries, since 2013 and gave the plenary lecture at CROI 2015 on this topic.

This trial was recently published in the New England Journal of Medicine and the data presented by Grinspoon at the International AIDS Society 2023 meeting in Brisbane and featured in news articles and podcasts.

[19][20][21][22][23] Grinspoon has worked to understand the mechanism, and treatment strategies for metabolic dysregulation in HIV, and was among the first to assess metformin and rosiglitazone to reverse insulin resistance and increase adipogenesis in this population.